Drug Approval | March 12, 2022
China approves BeiGene’s tislelizumab
Tislelizumab is now approved for seven indications in China
Tislelizumab is now approved for seven indications in China
Agreement builds on 15 years of successful collaboration between AbbVie and Richter, including globally launched cariprazine products
Selvax's goal is to develop safe, effective and immunological-based treatments for a range of hard-to-treat solid tumours
Nulibry is approved by the U.S. Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder
Cedars-Sinai Technology Ventures has had 114 patents issued for the fiscal year 2021 and has 511 active technologies under development, as of July 2021
Transformative closed-loop technology senses the spinal cord's response to stimulation and instantaneously adjusts therapy to sustain durable, optimized treatment
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
With over 20 years of international leadership experience, Dr. Amrein has led many teams and organizations across over 30 geographies
As the Covid-19 pandemic continues to have a disproportionate impact on women, Organon issues a call to action for other leaders to create opportunities to focus on women’s health
Toyobo will start looking at ways to use the knowhow from DMC’s sophisticated fermentation process technologies to enhance the efficiency of making its bioproducts
Subscribe To Our Newsletter & Stay Updated
